danazol has been researched along with Lymphoma, B-Cell, Marginal Zone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elefante, A; Przespo, E | 1 |
| Aish, L; Cooley, J; Gaur, S; Weinstein, R | 1 |
2 other study(ies) available for danazol and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Deep vein thrombosis associated with a single dose of romiplostim in a high-risk patient.
Topics: Bone Marrow Transplantation; Danazol; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Venous Thrombosis | 2012 |
Lymphoma-associated paraneoplastic angioedema with normal C1-inhibitor activity: does danazol work?
Topics: Adult; Angioedema; Complement C1 Inactivator Proteins; Danazol; Estrogen Antagonists; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Splenectomy; Splenic Neoplasms; Treatment Outcome | 2004 |